CSL Limited
Capitalisation boursière
$49.1B
Rang mondial
#264
Sommet historique
$85.2B
2023-12-31
Croissance totale
+0%
depuis 2026
Market Cap Context
- Larger than 28% of the 367 companies we track (globally).
- Equivalent to 2.7% of Australia's GDP (2025 data).
- Just above: #263 Becton, Dickinson and Company ($49.2B)
- Just below: #265 BASF SE ($48.7B)
- Best year: 2000 (+80%). Worst year: 2002 (-58%).
CSL Limited Financial Breakdown (FY 2025)
Source: Yahoo Finance — CSL.AX annual filings (2025) →$15.4B revenue · $3.0B operating income · $3.0B net income
- ●Operating margin: 19.2% on $15.4B in revenue.
- ●R&D is 8.8% of revenue ($1.4B).
- ●Net income margin: 19.5% — $3.0B in profit.
- ●Free cash flow: $2.5B (16.5% of revenue).
Cost / Operating Expenses
Total operating expenses $12.5B
Total
$11.5B
Capital Expenditures
$1.0B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$2.5B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
À propos de CSL Limited
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
Historique de la capitalisation boursière de CSL Limited (2026–2026)
CSL Limited vs Sector Peers by Market Cap
Comparer CSL Limited
Historique du classement
| Année | Capitalisation boursière | Rang | Variation sur un an |
|---|---|---|---|
| 2026 | $49.1B | #264(↓23) | -7.4% |
| 2025 | $53.1B | #241(↓91) | -37.5% |
| 2024 | $84.9B | #150(↓16) | -0.4% |
| 2023 | $85.2B | #134(↓24) | +0.9% |
| 2022 | $84.5B | #110(↑11) | +0.1% |
| 2021 | $84.4B | #121(↓17) | +3.7% |
| 2020 | $81.3B | #104(↓17) | +3.7% |
| 2019 | $78.4B | #87(↑10) | +50.8% |
| 2018 | $52.0B | #97(↑47) | +32.6% |
| 2017 | $39.2B | #144(↑20) | +42.7% |
| 2016 | $27.5B | #164(↓21) | -3.0% |
| 2015 | $28.3B | #143(↑26) | +23.7% |
| 2014 | $22.9B | #169(↑16) | +27.9% |
| 2013 | $17.9B | #185(↓11) | +30.1% |
| 2012 | $13.8B | #174(↑31) | +72.1% |
| 2011 | $8.0B | #205(↑2) | -9.4% |
| 2010 | $8.8B | #207(↓3) | +14.4% |
| 2009 | $7.7B | #204(↓41) | -1.6% |
| 2008 | $7.9B | #163(↑36) | -6.1% |
| 2007 | $8.4B | #199(↑27) | +68.8% |
| 2006 | $5.0B | #226(↑10) | +55.9% |
| 2005 | $3.2B | #236(↑2) | +47.7% |
| 2004 | $2.2B | #238(↑3) | +66.3% |
| 2003 | $1.3B | #241(↓22) | -15.6% |
| 2002 | $1.5B | #219(↓34) | -57.5% |
| 2001 | $3.6B | #185(↑2) | +32.6% |
| 2000 | $2.7B | #187(↓21) | +79.9% |
| 1999 | $1.5B | #166(↑2) | +58.6% |
| 1998 | $954.6M | #168(↑1) | +48.3% |
| 1997 | $643.5M | #169(↓4) | +64.6% |
| 1996 | $391.0M | #165(↓12) | +52.3% |
| 1995 | $256.7M | #153(↓14) | +71.4% |
| 1994 | $149.8M | #139 |
Autres entreprises du secteur Santé
FAQ
What is CSL Limited's market cap?
CSL Limited (CSL.AX) has a market capitalization of $49.1B, making it the #264 largest company in the world by market cap.
What was CSL Limited's highest market cap?
CSL Limited's all-time high market cap was $85.2B, reached in 2023-12-31. Its highest rank was #134 in 2023.
What sector is CSL Limited in?
CSL Limited is in the Healthcare sector, specifically the Biotechnology industry. It is based in Australia.
How has CSL Limited's market cap changed over time?
CSL Limited has been tracked since 2026. Its market cap has grown by 0% from $49.1B in 2026 to $49.1B today.